2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Liquid Biopsy For Cancer
Liquid biopsy stands as a groundbreaking advancement in cancer research, offering a non-invasive method to detect and monitor cancer through analyzing biomarkers present in bodily fluids like blood or urine. Unlike traditional tissue biopsies, which can be invasive and sometimes impractical for frequent monitoring, liquid biopsy provides a less burdensome alternative. By detecting circulating tumor cells, cell-free DNA, and other molecules shed by tumors into the bloodstream, liquid biopsy enables early detection of cancer, monitoring treatment response, and detecting recurrence with greater precision. Its potential extends beyond diagnosis, allowing for personalized treatment strategies based on the tumor's genetic profile. As research continues to refine and expand the utility of liquid biopsy, it holds promise for revolutionizing cancer management by offering a minimally invasive yet powerful tool in the fight against this complex disease.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China